Photo Gallery
Photos from February 2019 are now available to download and share - view the full photo gallery here.
BOOK NEXT YEAR'S TICKETS AT THIS YEAR'S PRICES
Until April, all passes to attend Animal Health Investment Europe 2020 will be frozen at 2019 rates - register soon to benefit!
Animal Health Investment Europe is a premier investment forum showcasing the most exciting investment opportunities in animal health and nutritional health, and connecting those businesses with financial investors and strategic corporate partners from 38 countries worldwide.
To complement our investment pitches, we host CEO-level discussions that address the trends and market dynamics of the animal health industry, across all species.
Networking is a large part of what we offer - across the two days you can meet face-to-face with decision makers from the full spectrum of the animal pharma and nutritional health industry: from our 200 start-ups (such as Proteon Pharma and REX Animal Health, the winners of the 2019 Innovaiton Showcase), to C-Suite leaders from 18 of the top 20 animal health companies (incuding Clint Lewis of Zoetis, Joachim Hasenmaier of Boehringer Ingelheim and Jeff Simmons of Elanco).
Book now at super early-bird prices to come and see for yourself!
Series Highlights
Apply for Next Year's Showcase
Get ahead of the game and apply for the Innovation Showcase 2020.
The standard of applications this February was exceptional, and we had over 60 emerging companies submit their technologies to the Selection Committee.
Due to high demand we are opening the 2020 Showcase early.
You can already apply, free of charge, via our form here.
Showcase applicants are eligible for a discounted ticket to come and meet the investors face-to-face at next year's meeting in February. All prices will be frozen at 2019 pricing until 1 April, so book soon to save.
Congratulations to all 24 of the 2019 Finalists, and thank you to the 60+ companies that applied to the Showcase.
Please click the "Innovation Showcase Finalists" PDF below to learn more about the most exciting innovations in animal health and nutrition from 2019...
Selection Committee
Charles Hoare
Matthias Hofer
Julia Stephanus
Michael Hemprich
Maarten Goossens
Martijn Adorf
Oliver Hardcastle
Jarne Ellenholm
Paul Dick
Isaac Fraynd
Advisory Board
Clinton Lewis
Joachim Hasenmaier
Dirk Ehle
George Gunn
Linda Rhodes
Aaron Schacht
Alan Mackay
Dr. James Lloyd
Sébastien Huron
Jean Deleforge
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
- Please note that a £49 processing fee will apply to any invoices requested.
- Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
- All Prices are in GBP
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- No discounts or offers can be combined.
- Please view our Cancellation Policy.
- Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate.
- Please Note: No additional discounts are available on ‘Emerging Company’ pricing.
The Speakers in 2019
Lord Alexander John Trees, Baron Trees
Lord Trees qualified as a veterinarian in 1969 and has worked in general practice, industry and, for most of his career, academia. In 1980 he was appointed Lecturer in Veterinary Parasitology at the University of Liverpool based in the Liverpool School of Tropical Medicine. He was Professor of Veterinary Parasitology from 1994 and Dean of the Faculty of Veterinary Science from 2001 – 2008. His research embraced livestock disease in both temperate and tropical environments, including a strong interest in One Health and parasitic infections as models of human tropical disease. He retired from the University in 2011.
He was President of the Royal College of Veterinary Surgeons in 2009-2010, and is currently Chair of the Moredun Research Institute Board, Veterinary Editor in Chief of the Vet Record and In Practice, and an Honorary Fellow of the Royal Society of Edinburgh.
In 2012 he was appointed a Crossbench Peer in the House of Lords Commission and is only the second veterinary surgeon to be appointed. There he has served on the EU Select Committee and its Sub-Committee on Energy and Environment (which included agriculture) and has participated in the production of 20 House of Lords Select Committee Reports published 2015-2017, many on the consequences of Brexit including on Brexit: Agriculture and Brexit: Farm Animal Welfare.
Joachim Hasenmaier
Joachim Hasenmaier, born 1960 in Vaihingen/Enz, Germany, DVM., is Member of the Board of Managing Directors of C.H. Boehringer Sohn AG & Co. KG since October 1, 2012, responsible for the Corporate Board Division Consumer Health Care and Animal Health. His nationality is German.
He received a veterinary medical degree (DVM) in 1986 from Ludwig-Maximilians-University, Munich, where he entered into a microbiological research program until 1989 receiving his Doktor med. vet. (PhD) degree. He completed his education with a Master in Management from Kellogg Business School, Chicago, USA in 1991. Prior to joining BI he worked in various positions for various international companies in Germany, Japan, Mexico and Brazil.
In 2002 he joined Boehringer Ingeheim as Corporate Senior Vice President for Boehringer Ingelheim Animal Health. In 2011 he took over the regional responsibilty for Prescription Medicine in NECAR (UK/Ireland, Nordics, Benelux, Canada, Australia/New Zealand). He held this position until he became Member of the Board of Managing Directors at C.H. Boehringer Sohn AG & Co. KG in October 2012.
Daan Luining
Daan Luining is Meatable’s CTO and scientific mastermind. Daan lives and breathes clean meat and has been involved since the earliest stages, having worked on the first lab grown hamburger in 2013. After that, Daan expanded his knowledge on the field at New Harvest, an NGO that funds academic research in cell-based meat.
Barney Kay
Clinton Lewis
Clint Lewis is executive vice president and president of International Operations at Zoetis. In this role, he oversees the management of the livestock and companion animal business markets outside the United States.
Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007.
Mr. Lewis joined Pfizer in 1988 as a sales representative in Long Island, N.Y., and has held positions of increasing responsibility in several areas across various commercial operations dedicated to human health prior to joining animal health, including vice president and general manager of Pfizer’s U.S. Anti-Infectives/HIV business unit.
In 2011, Mr. Lewis was elected chairman of the Animal Health Institute (AHI) for the 2011-12 term. A member of AHI since 2007, Mr. Lewis previously served as AHI vice chair for the 2009-2010 term. AHI is the trade association for the animal health industry in the U.S. advocating on various issues important to the industry, including efficient and effective regulatory and approval processes by the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), and the Environmental Protection Agency (EPA).
Mr. Lewis holds a bachelor’s degree in biology from Fairfield University and a Master of Business Administration in marketing from Fairleigh Dickinson University.
Jeff Simmons
Simon Innes
Simon was appointed as Chief Executive in January 2004. Prior to this he was Chief Executive of Vision Express from 2000 to 2004, over which time he built the business up to £220m turnover and 205 practices, and reversed a loss-making position to create one of the most profitable corporate optical operators in the UK. The growth strategy that was successful at Vision Express is now being implemented in the veterinary industry by CVS.
Prior to Vision Express, Simon was on the board of Hamleys PLC as Operations Director and gained 10 years’ management experience at Marks & Spencer. He also served seven years in the British Army, achieving the rank of Captain in the Royal Engineers.
David Hunt
Oliver Hardcastle
Kathy V. Turner
Mathieu Castex
Linda Rhodes
Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.
Davide Rossi
James Andrews
Aaron Schacht
Berwyn Clarke
Joseph Harvey
Brian Topper
Matt Dobbs
Mark Heffernan
Maarten Goossens
Maarten is a Co-founder and Principal at Anterra Capital. He began his investing career as an Analyst within the Rabo Ventures team in 2009 and was primarily responsible for deal sourcing and execution, and portfolio management.
Prior to joining Rabo Ventures, Maarten was an Analyst in the Rabobank-Rothschild M&A joint venture in London, where he focused on transactions in Food & Agriculture.
Maarten holds a Masters of Business Administration from the Free University of Amsterdam, and has studied at the London School of Economics.
Laëtitia Gerbe
Robin Hargreaves
Peter McCarthy
Mr. McCarthy is now in his 7th year at Henry Schein, Inc. He is currently the Company's President, Global Animal Health Group, as well as a member of Henry Schein's Executive Management Committee.
Mr. McCarthy oversees Henry Schein's animal health business, which spans 24 countries including the United States, Australia, New Zealand, Canada, China, Malaysia, Brazil and 17 countries in Europe.
Before assuming his current position, Mr. McCarthy held key roles at Henry Schein with increasing responsibilities, including President, Henry Schein Animal Health, Europe, and President, Henry Schein Animal Health, International.
Prior to joining Henry Schein, Mr. McCarthy worked at Schering-Plough Animal Health (now Merck Animal Health), serving as Senior Director, Global Operations and General Manager, China. Mr. McCarthy also worked at Wyeth/American Cyanamid for 14 years, helping to grow the human pharmaceutical business.
Mr. McCarthy holds a degree in Applied Biology from the University of Hertfordshire in the U.K., and previously has served as a Member of the Board of the International Federation for Animal Health Europe, and the International Association Executive Animal Health Study Center, CEESA, based in Belgium. Mr. McCarthy is also a graduate and member of the Chartered Institute of Marketing (CIM), which is located in the U.K.
Alan Mackay
Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.
Marcel Lacaze
Marcel joined Permira as a Principal in 2014 and focuses on the healthcare sector. Prior to joining Permira, Marcel worked for Novartis, leading the M&A activities for Novartis Consumer Health, Vaccines & Diagnostics. Before that, he spent eight years in investment banking working for Lazard and Merrill Lynch. Marcel holds degrees in Business Administration, Economics and languages from the University of Passau, Germany, as well as Bejing Yuyan Xueyan, China.
Cindy Barnes
Roy Stein
Antione Hubert
James Millar
Simon Doherty
Simon is the Senior Vice-President of the Northern Ireland Branch of the British Veterinary Association (BVA). He is an Honorary Lecturer at Queen’s University Belfast and a trustee of livestock development charity, Send a Cow. Simon graduated from the University of Glasgow Veterinary School in 2000 and his career has spanned general veterinary practice, animal health & welfare policy, diagnostics, research, epizootic disease preparedness and biotechnology; with a specific interest in the design of novel vaccines for food-producing animals.
Simon is the Animal Science Specialist for the Agri-Tech Organisation of UK Trade & Investment (UKTI). Using his broad knowledge of the animal health sector, coupled with an understanding of the UK Agri-Tech offer, Simon works with animal health companies – from SMEs to large multinationals – to maximise their opportunities by locating in the UK. In addition to technologies linked to livestock, his portfolio also includes companion animal and aquaculture innovation.
David Perin
Jean-Louis Hunault
My professional activity began as a lecturer in public law at the University of Paris 2 and Paris V and in 1988 as legal counsel and then director of economic and legal affairs of the Union of Plant Protection Industries - UIPP. Graduated from HEC's Executive MBA in 1993 I created and managed 2 companies in the environment and direct marketing sector. In 1996, I joined the veterinary medicine and diagnostics industry union - SIMV as secretary general. I was elected Chairman of the SIMV Board 5 times. My last term will cover the period 2018-2021.
I exercise different mandates: administrator of the national agency of health safety of the food, environment and work - ANSES, substitute member of the National Council of the higher education and the research (CNESER), secretary of the French network for animal health - RFSA.
At the European level, I am member of the Board of the European Federation of Animal Health - Animal Health Europe.
At the global level, I held the position of Director Europe for a five-year term on the Board of Directors of our World Federation (Heath for Animals).
I am the Secretary General of the World Veterinary Diagnostics Industry Federation - DiagnosticsforAnimals - an organization I created in 2007.
Kay O'Donnell
Eric Garcia
Mike Seely
Anthony Roberts
Anthony is responsible for the delivery of the strategic ambition to become a Royal College with leadership and innovation at its heart.
Leadership work includes the implementation of a programme to support the next generation of veterinary leaders and develop leadership opportunities across the veterinary professions, and the completion of the RCVS governance review to ensure that we are an effective and efficient organisation, better able to lead the profession and serve the needs of the public.
Innovation incorporates the development of initiatives to ensure the veterinary professions are at the centre of innovation in the animal health sector, to position the professions as open to innovation, and to ensure the RCVS serves to foster innovation whilst continuing to protect animal health and welfare.
Anthony also leads the development and delivery of a programme of work to prepare the College and the profession for the impact of Brexit and the implementation of evidence-based measures to drive the transition to a supportive ‘learning-culture’ in the veterinary professions.
Anthony has worked at the RCVS for seven years and has been responsible for delivering key projects such as the First Rate Regulator Initiative (2012/13) and the launch of the new Practice Standards Scheme (2015). Prior to joining the RCVS Anthony worked in public affairs and media relations at the British Plastics Federation, the trade association for the UK plastics industry.
Anthony holds an MBA from Warwick Business School (2016), an MA (Hons) in Philosophy and Politics from the University of Edinburgh (2004) and the CIPR Diploma in Public Relations (2009).
Marie Paul-Lachaud
Since 2013, Dr. Marie-Paul Lachaud has served as Head of Program Management Europe at Aratana Therapeutics Inc.. Her responsibilities include coordinating the process leading to regulatory approval by the European Medicines Agency for Aratana’s products, most recently GALLIPRANT.
Since 2009, Dr. Lachaud has also provided services to the veterinary pharmaceutical industry as an experienced independent consultant, with a specific focus on international clinical development and registration of animal drugs.
From 2000 to 2008, Dr. Lachaud was the European Animal Health Director at ICON Clinical Research in Paris, France. In 1990, she co-founded PROTOCOLE, the first European veterinary consultancy and Contract Research Organization dedicated to veterinary drug clinical development and regulatory affairs, which was acquired by ICON in 2000.
Throughout her career, Dr. Lachaud has been involved in transitioning human drugs to meet unmet needs in veterinary medicine. Her work has resulted in significant companion animal health product approvals in Europe and the United-States in a number of innovative therapeutic areas, including reproduction, atopic dermatitis, chronic heart failure, wound healing, chronic kidney disease, acute and chronic pain, obesity, inappetence, cancer, cognitive dysfunction and anxiety-related disorders.
She received her veterinary degree from Alfort National Veterinary School in Paris and her doctorate in veterinary medicine from the University of Paris, France.
Duncan Lascelles
B. Duncan X. Lascelles
BSc, BVSC, PhD, MRCVS, CertVA, DSAS(ST), Diplomate ECVS, Diplomate ACVS
Professor of Surgery and Pain Management
Director, Comparative Pain Research and Education Centre
Translational Research in Pain Programme,
North Carolina State University College of Veterinary Medicine, Raleigh, NC, 27606, USA
After graduating from the veterinary program at the University of Bristol, U.K., with honors, in 1991 Dr. Lascelles completed a PhD in aspects of pre-emptive/perioperative analgesia at the University of Bristol. After an internship there, he completed his surgical residency at the University of Cambridge, U.K. He moved to Colorado for the Fellowship in Oncological Surgery at Colorado State University, then a period of post-doctoral research in feline pain and analgesia at the University of Florida, and is currently Professor in Small Animal Surgery and Pain Management at North Carolina State University. He is board-certified in small animal surgery by the Royal College of Veterinary Surgeons, the European College of Veterinary Surgeons, and the American College of Veterinary Surgeons.
He is director of the Comparative Pain Research and Education Centre (CPREC). His research program (Translational Research in Pain [TRiP]) is dedicated to answering critical questions about pain control and pain mechanisms through high quality, innovative research. His career has been focused on developing algometry methods (methods to measure pain) in spontaneous disease animal models (pets with naturally occurring disease), and probing tissues from well-phenotyped animals with spontaneous disease to understand the neurobiology, with a strong translational focus. The aim of his research is to improve pain control in companion animals, and facilitate analgesic development in human medicine. He has authored over 180 peer reviewed research papers and reviews and 190 research abstracts, as well as over 30 book chapters.
He has worked closely with industry partners in both animal and human health, helping to re-define the relationship between industry and academia. Through reviews and invited presentations he advocates for the use of spontaneous disease in animals to inform human therapeutic development. Recently, he organized a meeting of industry, academia, regulatory authorities (FDA) and the NIH to discuss measurement of chronic pain in companion animals and the application to human pain research (www.PAW2017.com), and is planning PAW2019. He is completing a year-long integrated sabbatical within a pain therapeutic company (Centrexion Therapeutics) that develops novel therapeutics for both humans and animals. He provides consulting services related to pain therapeutic development across all stages of animal therapeutic development, and for pre-clinical and Phase I stages of human therapeutic development.
Through his work in academia and industry, he contributes to and facilitates the development of novel pain therapeutics for companion animals, and advocates for the use of spontaneous disease in pets to inform human pain therapeutic development.
Dirk Ehle
Dr. Dirk Ehle has been a member of the Bayer HealthCare Executive Committee and responsible for the Animal Health Division since May 1, 2012.
Dirk Ehle was born on May 26, 1969, in Cologne, Germany. He studied law at the universities of Freiburg, Aix-en-Provence (France), Wurzburg, and New York (USA).
After three years in law firms, Dirk Ehle started his career at Bayer in 2001 in the Law Department of Bayer HealthCare. In 2006, Ehle transferred to Bayer AG’s Corporate Office where he worked as Executive Assistant to the Chairman of the Board of Management. He was also in charge of Corporate Policy & Advocacy as of 2008. In 2010, Ehle was appointed Senior Bayer Representative for Central Eastern Europe and Bayer HealthCare Representative for Poland.
Dirk Ehle is married with three children.
Bénédicte Flambard
Bénédicte Flambard currently is heading the Business Unit of Live Therapeutics & Nutraceuticals at Boehringer Ingelheim. She leads the creation of a new business area at the interface of Therapeutic Nutrition and Health, combining novel microbial based bio-therapeutic and diagnostic approaches.
Previously, Bénédicte worked for Merial and for Chr. Hansen, the world Leader in Microbial Solutions. She hold several Vice President positions across commercial and innovation areas, dedicated to Health Supplements for Pharma, OTC, Infant Formula as well as Agricultural Industries (Animal Feed & Plant). While growing core businesses, she was seeding and developing Growth Opportunities into Start Up businesses- one focusing exclusively on Microbiome.
She holds several trustee positions as Board Member at the Quadram Institute, as well as diverse Advisory roles to organizations in the sectors of consumer goods, pharmaceuticals and technology.
Bénédicte holds a Master of Administration, with specialties in business models in emerging economies from the University of Bath in the U.K.; a PhD in Molecular Genetics and Microbial Physiology from INRA (National Institute of Agronomic) in France; and a Master in Corporate Entrepreneurial Leadership from the Centre for Technology Economics & Management in Denmark.
Emma Harris
Jennifer Filbey
Jolyon Martin
Joost Matthijssen
Justine Conway
Kenneth Lee
For the past two decades, Ken has worked with global leaders of the food and consumer care industry to leverage early stage science into game-changing innovations. He cut his teeth at L’Oréal, where he established a process enabling the company to take advantage of opportunities that arise in a fast-changing world. Ken led the Strategic Foresight function for the L’Oréal Group and undertook missions in Brazil, China, India, Israel, Japan and the US.
Ken moved to Singapore in 2013 to join the Agency for Science, Technology & Research (A*STAR), where he played a pivotal role in architecting the strategy to establish Singapore as a leading science and innovation hub for the food, nutrition and consumer care industry. Ken and his team were successful in securing more than S$170 million in funding from the Singapore government to support new R&D programmes that address the key industry drivers of efficacy, safety and sustainability. These programmes helped to attract new investments by some of the largest companies in food and consumer care (CAGR +31%); and created an ecosystem comprising global brand owners, ingredients innovators and start-up companies.
Ken holds a PhD from the University of Edinburgh, and undertook doctoral and post-doctoral research in stem cells. He has been a member of New Protein Capital’s Investment Committee since 2016, stepping down in August 2018 when he was appointed Senior Partner.
Nick Hill
Starting out as a physicist, he studied at Oxford University before switching to Cambridge University for a PhD in quantum physics of semiconductor devices.
After completion of his PhD, Nick worked for Cambridge company NXT, he helped develop its revolutionary audio technology, which over the years proved an exceptional training ground in many areas including research management, product development, patents, and IP protection.
During this time, his passion for invention and entrepreneurship saw his career path take a different trajectory. Bitten by the start-up bug, he went on to develop an innovative cat flap for his cat (Flipper) – releasing the Microchip Cat Flap in 2008.
Following the global success of the Sure Petcare range of microchip reading pet door and feeders, Sure Petcare became part of the Antelliq family in 2015. Nick now heads the Antelliq consumer pet division. Where combining the of using a pet’s microchip and connected products is enabling the future of intelligent pet care.
Sébastien Huron
Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.
Sébastien Lafon
Bruno Cluzel
Bruno Cluzel is Executive Director, International Operations, Diagnostics Customer Care for Zoetis. In this role, he is responsible to define guidelines for customer and technical support services delivered in the markets; deliver elevated technical support and instrument repair; provide guidance to the Diagnostic Application Specialists in-market technical support; and develop and help deliver training curriculum, materials and sessions.
Bruno has extensive experience working within the animal health care sector. Through his career, Bruno has held various roles working across a number of different functions and regions.
With a passion for animal health, Bruno holds a diploma of Veterinary Medicine and started his career as a Practitioner specialized in Production Animal with a focus on Avian Medicine. After 15 years in this role, he joined Merial where he had different roles across Europe Africa and Middle East: technical, marketing and business lead. He joined Pfizer Animal Health in 2011 to help entering the Diagnostics. In his current role, he is building Customer Care capabilities as Zoetis expands around the Globe.
Rachel Dean
Dr Rachel Dean BVMS PhD MSc(EBHC) DSAM(fel) SFHEA MRCVS is a graduate from University of Glasgow and has worked in mixed, dairy and small animal general practice. She is holds the RCVS diploma in feline medicine, has a PhD in epidemiology and an MSc in Evidence-based Healthcare. She was the founding director of the Centre for Evidence-based Veterinary Medicine and a Clinical Associate Professor in Feline Medicine at the University of Nottingham from 2009-2018. Rachel is currently the Director of Clinical Research and Excellence in Practice and co-chairs the clinical board for VetPartners. Rachel is responsible for supporting the clinical teams to constantly improve standards of care across the business and encourage clinical leadership through research, innovation and professional development.
2019 saw a special opening welcome from Lord Alexander John Trees, Baron Trees, Professor of Veterinary Parasitology and a Crossbench member of the House of Lords.
Lord Trees qualified as a veterinarian in 1969 and has worked in general practice, industry and, for most of his career, academia. As Dean of the Faculty of Veterinary Science at the University of Liverpool his research embraced livestock disease in both temperate and tropical environments, including a strong interest in One Health and parasitic infections as models of human tropical disease.
Lord Trees was President of the Royal College of Veterinary Surgeons in 2009-2010, and is currently Chair of the Moredun Research Institute Board, Veterinary Editor in Chief of the Vet Record and In Practice, and an Honorary Fellow of the Royal Society of Edinburgh.
In 2012 he was appointed a Crossbench Peer in the House of Lords Commission and is only the second veterinary surgeon to be appointed.
The Agenda
We're still working on the 2020 agenda, but you can download this year's agenda here for a snapshot of what to expect.
Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.
Alongside our renowned animal health track, which brings you a showcase of the most exciting investment opportunities and novel technologies in animal health, brand new for 2019 was our dedicated nutrition investment forum, a veterinary practice track and also a human health partnerintg track.
Download the 2019 agenda to learn more...
Download the 2019 Agenda
Partners
Animal Health Investment Europe is supported by the most influential bodies across the Animal Health, Nutrition and Veterinary industries.
Be one of them, communicate about the event to your network, spread the word and become a Supporter of the Animal Health Investment series.
Senior Event Partners 2020
Clinvet
Website: http://www.clinvet.com
Clinvet is a GCP/GLP accredited Contract Research Organisation (CRO) established in 1999 and specialises in the conduct of laboratory and field-based efficacy, safety and metabolism trials for veterinary health products.
Since inception, Clinvet has conducted more than 1300 studies aiding in the discovery, development and registration of veterinary products worldwide.
Services offered by Clinvet
Laboratory in vitro and in vivo efficacy studies as well as safety and metabolism studies for animal medicine. We maintain an extensive bank of parasites (helminths and arthropods) originating from the US, EU and Africa for use in challenges on companion and production animals. Test animals frequently used include rats, rabbits, cats, dogs, goats, sheep, cattle and horses. We offer the following studies:
- Glass vial contact assay
- Artificial membrane feeding assay
- Proof of concept efficacy
- Dose determination and confirmation
- Parasite challenge efficacy
- Bioequivalence
- Pharmacokinetics
- Residue depletion
- Target animal safety
Clinical trial conduct as well as the following support services for animal clinical field and laboratory studies:
- Project management, monitoring and quality assurance
- Protocol, report writing and case report form (CRF) design
- Electronic database, design and validation (EDC/Paper)
- Data management, biostatistics and statistical programming
- Serological (IFA and ELISA) and molecular (qPCR and PCR) diagnostic testing
- Specialised molecular assay development
- Animal genetic profiling, parentage and mutation screening
- Genomic analysis of parasites
For more information, visit www.clinvet.com
Klifovet
Website: http://www.klifovet.com
KLIFOVET provides high quality services for the animal health and animal nutrition industry regarding the registration and marketing of all kind of veterinary products. We support ambitious young biotech and veterinary pharma companies on their way to the top by providing full business and product development management, regulatory affairs consultancy including dossier writing, compilation and submission, and full CRO services for safety and efficacy studies. We are proud on 18 years of experience, well organized logistics, a highly motivated team, and a comprehensive net of co-operators and skilled investigators throughout Europe, North America and the world. We handle large multinational projects as professionally as national ones, complying to national, EMA, EFSA or FDA standards.
Event Partner
Argenta
Website: http://www.argentaglobal.com
Argenta Limited, founded in 2006, is the world’s only combined contract research organization (CRO) and contract manufacturing organization (CMO) specializing in animal health. With accredited operations and facilities across New Zealand, the United States and Scotland, Argenta is fully equipped to offer a full range of products and services - from access to innovative intellectual property, formulations research and development (R&D), analytical methods development, clinical trial management through to pilot- technical transfer and commercial-scale manufacturing - to the global animal health industry. Argenta’s 400+ global team develops and exports products and services to over 40 countries.
A privately-owned company headquartered in Auckland, New Zealand, Argenta brings innovation, R&D and manufacturing expertise together in one global company. This makes it ideally placed to accommodate unique product requirements no matter the scale or complexity. Argenta’s facilities in New Zealand, the United States (Iowa, Kansas and New Jersey) and Europe (Scotland) enable the achievement of significant efficiencies in product development and technology transfer, and to provide market intelligence and in-depth knowledge of market preferences in different countries as required.
Argenta is honoured to work with a vast range of clients globally - from small and medium-sized enterprises (SMEs) to some of the largest industry players. Argenta has the R&D capabilities and manufacturing scale to service the requirements of the largest multinationals, while, at the other end of the spectrum, Argenta works with startups and small companies with great ideas to help them find solutions and bring their ideas to fruition.
For more information, please visit www.argentaglobal.com.
Triveritas
Website: http://www.triveritas.com
Triveritas is a veterinary CRO with local offices in Europe and North America providing assistance in the development and registration of biological and pharmaceutical products in Animal Health. With a global customer base, both start-up and Top 10 Animal Health companies count amongst returning customers. Regulatory Affairs services, from initial strategic advice to final submission of dossiers, are provided by a highly competent team, including biologicals and pharmaceuticals specialists, a toxicologist, CMC/Part II experts and Qualified Persons for Pharmacovigilance. An integrated approach to project management has lead to proven success in the approval of products at EMA, FDA, USDA and EPA. Clinical Studies, compliant to VICH GCP, are performed by fully trained, experienced Monitors, veterinarians, data managers and support scientists, together with collaborating Investigators and laboratories. Independent Quality Assurance auditors provide inspection services in VICH GCP/GLP/GMP.
Become a Sponsor
Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at partner@kisacoresearch.com.
Press Partnerships
Whether you are an association, embassy, industry body or publication, we can offer a tailored marketing partnership to suit your needs. As a Media Partner we can:
- Promote your organisation as an event partner across all conference materials, including the website, brochure, emails and on-site programme
- Offer your members or readers a discount on their registration fee for Animal Health Investment Europe
- Provide one free press pass to attend
- Distribute promotional materials at the conference
If you are a registered industry journalist or member of the press and would like to arrange an interview with a speaker or to discuss the event please contact:
Jessica Parry
Senior Marketing Manager
T: +44 (0)203 696 2920
E: [email protected]
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.